Company intelligence / Profile preview

FEI25 Collective Intelligence Startup Competition

Boston, MA, USA

Ownership: Private
Development stage: Other

Overview

Neoclease is a seed-stage biotechnology company focused on advancing the field of precision gene editing through an AI-driven platform. The company's technology leverages generative AI to design gene-specific nucleases with enhanced precision and safety profiles compared to traditional methods. Its lead therapeutic program is directed at the LRRK2 gene, a primary driver of Parkinson's disease. Neoclease gained significant industry recognition by winning the first-place prize at the FEI25 Collective Intelligence Startup Competition in 2025.

Therapeutic areas: Neurology
Modalities: Gene editingGene therapy
Industry: Biotech

Partnerships

LabCentral AI BioHubC10 Labs

Beyond the preview

Go deeper on FEI25 Collective Intelligence Startup Competition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FEI25 Collective Intelligence Startup Competition.

Explore the full profile